Current Status of Molecular Imaging in Inflammatory and Autoimmune Disorders

Author(s): Alberto Signore*, Kelly Luz Anzola, Sveva Auletta, Michela Varani, Agnese Petitti, Marta Pacilio, Filippo Galli, Chiara Lauri

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 7 , 2018

Become EABM
Become Reviewer
Call for Editor


In the field of inflammation imaging, nuclear medicine techniques can be considered as a non-invasive tool to early detect pathophysiological changes in affected tissues. These changes usually occur before clinical onset of symptoms and before the development of anatomical changes, that are commonly detected by radiological procedures. This is particularly important for prognostic purposes, therapy decision making and for therapy follow-up. Here we review the current state-of-the art of nuclear medicine for diagnostic purposes in different conditions characterized by a chronic inflammation, such as vulnerable atherosclerotic plaques, vasculitis, rheumatoid arthritis, Sjogren syndrome, autoimmune thyroid diseases, inflammatory bowel diseases, Coeliac disease, Type 1 diabetes mellitus and other immunological diseases. Overall, we describe several different approaches based on radiolabeled cells, peptides and antibodies or FDG. It emerges the role of PET and of hybrid cameras in particular (SPECT/CT and PET/CT) for diagnosis of these disorders and for therapy decision making and followup.

Keywords: Molecular imaging, inflammation, nuclear medicine, atherosclerotic plaques, vasculitis, antibodies.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 14 May, 2018
Page: [743 - 753]
Pages: 11
DOI: 10.2174/1381612824666180130115153
Price: $65

Article Metrics

PDF: 55
HTML: 18